Pregnancy Clinical Trial
Official title:
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery
This research study is being conducted at over 12 pregnancy research centers in the US. The study will compare an investigational treatment with a placebo (a treatment without medication). Neither the investigators nor the patients in the trial will know which treatment has been assigned. All study medications will be given vaginally once a day. Treatment will begin before pregnancy week 23 and will continue until the end of pregnancy week 36.
Status | Completed |
Enrollment | 636 |
Est. completion date | March 2009 |
Est. primary completion date | January 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. The subject has a history of a documented spontaneous singleton preterm delivery (hospital or clinic record, letter from healthcare provider, or birth certificate) from 20 0/7 to 35 0/7 weeks gestational age with the immediate preceding pregnancy or has a cervical length of 2.5 cm or less measured by transvaginal ultrasound with the current pregnancy. "Spontaneous preterm delivery" is a delivery (<35 weeks), either vaginal or cesarean, that is initiated by either preterm PROM followed by contractions or preterm labor initiated with in-tact membranes. A previous preterm delivery secondary to an incompetent cervix where a cerclage is considered for this pregnancy is not considered a preterm delivery (please see Exclusion Criteria No. 10). Subjects enrolled based on a history of preterm delivery may have had a pregnancy loss (or losses) at <20 0/7 weeks gestational age between the preceding preterm delivery and the current pregnancy. 2. The female subject is between 18 and 45 years of age at the time of screening. 3. The pregnancy has an estimated gestational age between 16 0/7 weeks and 22 6/7 weeks. 4. The subject speaks either English or a common local language. 5. The subject has voluntarily signed the Informed Consent Form and associated forms after having the contents explained, and all her questions are answered to her satisfaction and understanding. 6. In the opinion of the investigator, the subject is able to understand the study and is able to give informed consent, as well as participate in it and adhere to study procedures. Exclusion Criteria: 1. The subject has a previous history of an adverse reaction to progesterone or any component present in Prochieve® 8% vaginal gel. 2. The subject has been treated with a progestogen within the previous 4 weeks. 3. The subject is currently being treated for a seizure disorder, has an unstable psychiatric disorder, is taking antihypertensive therapy for chronic hypertension at the time of enrollment, has a history of congestive heart failure or chronic renal failure, or has uncontrolled diabetes mellitus (known end-organ dysfunction secondary to vascular disease). 4. The subject has active thrombophlebitis or a thromboembolic disorder, or a history of hormone-associated thrombophlebitis or thromboembolic disorders. 5. The subject has liver dysfunction or disease. 6. The subject has known or suspected malignancy of the breast or genital organs. 7. The subject is currently participating in another investigational study or has participated in an investigational drug study within one month prior to screening for this study. 8. The subject's current pregnancy is complicated by a major fetal anomaly or known chromosomal abnormality. 9. The subject has a uterine anatomic malformation (bicornuate uterus, septate uterus) 10. The subject has a multifetal gestation. 11. The subject has a cervical cerclage in place or has plans to have one placed during the current pregnancy. 12. The subject, in the judgment of the investigator, will be unable or unwilling to comply with study-related assessments and procedures. 13. The subject currently has preterm rupture of membranes, vaginal bleeding, known or suspected amnionitis, or signs or symptoms of preterm labor at the time of enrollment. 14. The subject is HIV positive with a CD4 count of _<350 cells/mm3 and is receiving more than 1 medication to prevent the transfer of AIDS to the fetus. 15. The subject has placenta previa or a low-lying placenta. The subject will be considered for the study if she is not at risk for increased bleeding and has not been given any vaginal precautions. 16. The subject's qualifying preterm delivery was an indicated delivery without preterm labor (i.e. delivery performed for fetal distress, maternal eclampsia/preeclampsia, fetal death, or amnionitis in the absence of contractions). |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | University of New Mexico | Albuquerque | New Mexico |
United States | Northside Maternal Fetal Specialists | Atlanta | Georgia |
United States | Womens Partner In Health | Austin | Texas |
United States | Johns Hopkins Community Physicians | Baltimore | Maryland |
United States | Maternal Fetal Medicine &Woman's Health Research | Baton Rouge | Louisiana |
United States | Ohio Permanente Medical Group | Bedford | Ohio |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | St. Elizabeth's Medical Center -MFM | Brighton | Massachusetts |
United States | Jacobi Medical Center | Bronx | New York |
United States | Montefiore Medical Center | Bronx | New York |
United States | Cooper University Hospital | Camden | New Jersey |
United States | Regional Obstetrical Consultants | Chattanooga | Tennessee |
United States | University of Chicago | Chicago | Illinois |
United States | University of Illinois | Chicago | Illinois |
United States | University of Cincinnati | Cincinnati | Ohio |
United States | MacDonald Clinical Trials Unit, University Hospitals of Cleveland | Cleveland | Ohio |
United States | Women's Health Department | Colton | California |
United States | Health Central Women's Care | Dallas | Texas |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | Kaiser Permanente | Denver | Colorado |
United States | Pitt County Memorial Hospital | Greenville | North Carolina |
United States | University Medical Group, Dept of OB/GYN | Greenville | South Carolina |
United States | Clinical Research Center of Houston | Houston | Texas |
United States | Central Baptist Hospital | Lexington | Kentucky |
United States | Department of OBGYN, St. Barnabas Medical Center | Livingston | New Jersey |
United States | Maternal Fetal Medicine Norton Suburban Hospital | Louisville | Kentucky |
United States | Texas Tech University Health Sciences Center | Lubbock | Texas |
United States | Gynecology & Obstetrics | Memphis | Tennessee |
United States | University of South Alabama Department of OBGYN | Mobile | Alabama |
United States | West Virginia University | Morgantown | West Virginia |
United States | St. Luke's - Roosevelt Hospital | New York | New York |
United States | EVMS Maternal-Fetal Medicine, Hofheimer Hall | Norfolk | Virginia |
United States | Texas Tech Health Sciences Center - Odessa | Odessa | Texas |
United States | Temple University Medical Center | Philadelphia | Pennsylvania |
United States | SanDiego Perinatal Center | San Diego | California |
United States | Memorial Health University Medical Center | Savannah | Georgia |
United States | Louisiana State University Health Sciences Center-Shreveport | Shreveport | Louisiana |
United States | Holy Cross Hospital | Silver Springs | Maryland |
United States | St. Louis University | St. Louis | Missouri |
United States | Washington University | St. Louis | Missouri |
United States | The Toledo Hospital | Toledo | Ohio |
United States | Harbor - UCLA Medical Center | Torrance | California |
United States | Visions Clinical Research-Tucson | Tucson | Arizona |
United States | Abington Primary Women's Healthcare | Willow Grove | Pennsylvania |
United States | Lyndhurst Gynecologic Associates | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Juniper Pharmaceuticals, Inc. |
United States,
da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003 Feb;188(2):419-24. — View Citation
DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, Porter K, How H, Schakis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Cal — View Citation
O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Ca — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of delivery <=32 weeks | 18 weeks gestation through delivery | No | |
Secondary | Frequency of delivery preterm | 18 weeks gestation through delivery | No | |
Secondary | Response to tocolytic therapy | Onset of preterm labor through resolution or delivery | No | |
Secondary | Number of infant hospital days from delivery to discharge | Delivery date through hospital discharge date of infant | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT02379728 -
Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth
|
N/A |